A New Immuno-Resolving Treatment Paradigm for Inflammatory Bowel Disease (IBD)
IBD is a group of disorders characterized by inflammation and ulceration of the small and large intestines. The two major types of IBD are Ulcerative Colitis, which occurs in the colon and rectum, and Crohn’s Disease, which affects tissue throughout the intestinal tract.
Existing therapies for inflammatory bowel disease (IBD) work by blocking or inhibiting key steps in the inflammatory process. As a result, they can cause systemic immunosuppression potentially leading to undesirable side effects, along with increased risk of infection and malignancy. Moreover, up to 50% of patients treated with current therapies are non-responsive or experience relapse within 12 months of a prior flare. Thus, there is a clear need for additional therapeutic options.
Thetis is developing novel "immuno-resolving" therapies to treat IBD based on resolving inflammation and promoting tissue regeneration without suppressing normal immune function. Thetis agents deliver endogenous bioactive lipids that play a critical role in regulating the inflammatory immune response. Thetis achieves this through a proprietary technology platform that unlocks the potent pharmacology of these lipids as new molecular entities.
Thetis has two candidates in preclinical development. TP-317 is a unique derivative of a Specialized Pro-Resolving Mediator, a class of bioactive lipids that have been shown to activate innate pathways to control gastrointestinal inflammation and gut mucosal immune responses at very small therapeutic doses. TP-317 has the potential to be an induction and maintenance agent for patients failing first-line 5-ASA therapy as an alternative to immunosuppressive "step-up" therapies that pose a greater risk of significant side effects. TP-252 is a unique derivative of eicosapentaenoic acid, which has been shown in an academic Phase 2 trial to be effective in treating ulcerative colitis. TP-252 is targeted as adjunct over 5-ASA therapy to avoid escalation to step-up therapies.